\
&
Contact us
\
&
Contact us
Published on | 6 years ago
Programmes ERCERCEA has published a Call for Expression of Interest in view of establishing a Reserve List of Seconded National Experts in 7 profiles:
1. Communication Officer (Global outreach and events)
2. Communication Officer (Promotion of ERC projects and their results)
3. Ethics Officer
4. Research Programme Expert (Systems and Communications Engineering)
5. Research Programme Expert (Products and Processes Engineering)
6. Research Programme Expert (Earth System Science)
7. Auditor/Audit Liaison Officer
All information can be found in the published vacancy on the website of ERC: https://erc.europa.eu/about-erc/careers
The deadline for applications for the ERCEA Call for Expression of Interest – Seconded National Experts (ERCEA/SNE/176/2019) has been extended to Friday, 21 June 2019.
Application procedure:
1. The interested candidates should contact their Permanent Representation:
Please address your candidacy to relex.belgoeurop@diplobel.fed.be and include vlaanderen@diplobel.fed.be in cc.
2. The Permanent Representation should then send all applications to the mailbox ERC-SELECTION@ec.europa.eu at the latest by Friday, 21 June 2019 at 12:00 (midday) Brussels time. Please note that applications must be forwarded by the Permanent Representations. Applications sent directly to ERCEA will not be taken into account.
SNEs have to be employed by a national, regional or local public administration or an intergovernmental organisation.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
